Why the study?
Does rabeprazole reduce gastrointestinal bleeding or increase major adverse cardiac events in patients receiving dual-antiplatelet therapy after drug-eluting stent implantation?
Population
302 patients receiving dual-antiplatelet therapy after drug-eluting stent implantation
Comparison
Rabeprazole added to dual-antiplatelet therapy vs Dual-antiplatelet therapy alone
Design
Cohort
Authors
Loading...
No clear support for routine rabeprazole with DAPT post-DES; leaves open need for RCTs on GI and MACE effects.
Does rabeprazole reduce gastrointestinal bleeding or increase major adverse cardiac events in patients receiving dual-antiplatelet therapy after drug-eluting stent implantation?
Concomitant use of rabeprazole with clopidogrel and aspirin after DES implantation did not significantly reduce GI bleeding or increase the risk of MACE.
Yasu et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: